Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$25.75M+3306.35%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen F. Mahoney
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 252
- Beta
- 0.96
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.01
Financials
Revenue
$25.75M+3306.3%Net Income
$-101.21MEBITDA
$-101.13MFree Cash Flow
$-93.14MEPS (diluted)
$-0.81Shares Outstanding (diluted)
113.41M+14621.4%Operating Expenses
$127.70MCash & Debt
$955.21MReturn of Capital
$0.00Revenue by Segment (annual)
$70.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $70.85M | $-342.60M | $-3.32 |
| 2024 | $302.0K | $-269.95M | $-3.98 |
| 2023 | $314.0K | $-237.73M | $-5.31 |
| 2022 | $1.77M | $-129.87M | $-3.91 |
| 2021 | $2.96M | $-79.41M | $-6.66 |
| 2020 | $1.05M | $-110.72M | $-31.20 |
| 2019 | $4.46M | $-41.87M | $-20.31 |
| 2018 | $8.39M | $-32.70M | $-16.57 |
| 2017 | $4.00M | $-26.51M | $-20.66 |
| 2016 | $3.34M | $-12.67M | $-17.57 |
| 2015 | $2.54M | $-11.33M | $-21.00 |
| 2014 | $4.32M | $-7.89M | $-52.46 |
| 2013 | $4.32M | $-2.16M | $-11.48 |
| 2012 | $4.41M | $-7.21M | $-38.75 |
Valuation
VRDNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (9)
- Newsproactiveinvestors.com·3d ago·Positive
Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target Bank of America (BofA) has initiated coverage of Viridian Therapeutics (Nasdaq: VRDN) with a 'buy' rating and a $47 price objective, citing the potential of its thyroid eye disease treatments to capture market share and expand an undertreated market. The brokerage sees strong commercial prospects for Lumvoa, which is emerging as a challenger to Amgen's Tepezza, the current standard of care with annualized global sa…
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript Viridian Therapeutics, Inc. ( VRDN ) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans November 9, 2026 8:00 AM EST Company Participants Greg Rossino Stephen Mahoney - CEO, President & Director Radhika Tripuraneni - Chief Medical Officer Shan Wu - Chief Business Officer Conference Call Participants Faisal Khurshid - Jefferies LLC, Research Division Alexander…
View source ↗ - Newsbusinesswire.com·13d ago·Positive
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potential…
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead Viridian Therapeutics delivered a strong Q3, with Lumvoa net sales of $24.7 million, far surpassing consensus expectations. Competition is intensifying with Roche's Enspryng entering the TED market, but I see Lumvoa as well-positioned for continued growth, with more growth expected to come from elegrobart in late 2027. VRDN's near-term focus is on phase 1 data for VRDN-008 in the FcRn franchise, with expectations for deep IgG lo…
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call Viridian Therapeutics NASDAQ: VRDN reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment's first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript Viridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main OTTAWA, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) (“Viridian” or the “Company”) has intersected 15.05 metres at 1.09% CuEq within 40.8 metres at 0.63% CuEq, approximately 1.5 kilometres south of previous drilling at its Kraken copper-nickel-cobalt project in Labrador. The results are the first assays from the Company's southern step-out drilling program.
View source ↗ - Newsseekingalpha.com·66d ago·Neutral
…ucts, One Commercial Buildout Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.72 per share
Typical surprise +8.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.81 vs $-1.02beat
- Thu, Aug 6$-1.05 vs $-1.03miss
- Tue, May 5$-0.90 vs $-1.06beat
- Thu, Feb 26$-1.08 vs $-0.90miss
- Wed, Nov 5$-0.34 vs $-0.82beat
- Wed, Aug 6$-1.00 vs $-1.00beat
Estimates and results for VRDN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VRDN officers and directors.
- Bought
- $70.6m
- Sold
- $379k
6 trades
3 trades
- Tousignant Jennifersold
- Fairmount Funds Management Llcbought
- Tousignant Jennifersold
- Fairmount Funds Management Llcbought
- Beetham Thomas W.bought
- Mahoney Stephen F.bought
- Fairmount Funds Management Llcbought
- Fairmount Funds Management Llcbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VRDN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
